Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | FSHR | P23945 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 2/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | AOC2 | O75106 | 2/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
| ▸ | CTSS | P25774 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7184587 | 0.78 | CYP4F2 (0.35) | — | |
| SCHEMBL27390294 | 0.78 | MEN1 (0.38) | CTSLAPLNRTDP1MAOBMAOA | |
| SCHEMBL22604486 | 0.78 | HCRTR2 (0.41) | APLNRTDP1TSHRMAOBMAOA | |
| SCHEMBL23842466 | 0.78 | MEN1 (0.38) | CTSLAPLNRTDP1MAOBMAOA | |
| Methylamine SCHEMBL6804391 | 0.77 | CYP4F2 (0.34) | — | |
| SCHEMBL13157085 | 0.72 | THRB (0.33) | TSHRKMT2A | |
| SCHEMBL8254109 | 0.71 | HCRTR2 (0.39) | CTSLTDP1TSHRMAOBMAOA | |
| SCHEMBL30970108 | 0.70 | HCRTR2 (0.38) | CTSLTDP1TSHRMAOBMAOA | |
| SCHEMBL29318901 | 0.70 | HCRTR2 (0.38) | CTSLTDP1TSHRMAOBMAOA | |
| SCHEMBL22291484 | 0.69 | FOLH1 (0.39) | CTSLAPLNRTDP1MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058857-A1 | Method of treating cancer | YAO SIU-LONG (US) | 2004-03-25 | — | — | US | disclosed |
| EP-1009420-B1 | CONJUGATES USEFUL IN THE TREATMENT OF PROSTATE CANCER | MERCK & CO INC (US) | 2003-12-17 | — | — | EP | disclosed |
| US-20020042375-A1 | Method of treating cancer | HEIMBROOK DAVID C (US) | 2002-04-11 | — | — | US | disclosed |
| US-20020041880-A1 | Method of treating cancer | DEFEO-JONES DEBORAH (US) | 2002-04-11 | — | — | US | disclosed |
| US-6127333-A | COMPRISING OLIGOPEPTIDES, HAVING AMINO ACID SEQUENCES THAT ARE SELECTIVELY PROTEOLYTICALLY CLEAVED BY FREE PROSTATE SPECIFIC ANTIGEN AND KNOWN CYTOTOXIC AGENTS, CHARACTERIZED BY A DIAMINE LINKER BETWEEN THE OLIGOPEPTIDE AND VINBLASTINE | MERCK & CO., INC. (US) | 2000-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042375-A1 | Method of treating cancer | ACP3, KLK3, FOLH1 | CTSL 770/4885APLNR 452/4885NFKB1 952/4885 |
| US-20040058857-A1 | Method of treating cancer | KLK3, SHBG, ACP3 | CTSL 859/4885APLNR 563/4885NFKB1 1272/4885 |
| US-20020041880-A1 | Method of treating cancer | ACP3, FOLH1, KLK3 | CTSL 623/4885APLNR 156/4885NFKB1 2544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.